Vitamin D occupies a peculiar position in nutritional medicine: it is simultaneously ubiquitous - synthesised in the skin through mere exposure to sunlight - and alarmingly deficient across populations that would seem, on the surface, to have little reason to lack it. People living near the equator, farmers who spend their days outdoors, and adolescents in tropical low- and middle-income countries regularly present with clinically meaningful vitamin D deficiency. Understanding why requires moving beyond the simple narrative of sunlight and diet, and engaging instead with the full complexity of skin pigmentation, cultural practice, atmospheric pollution, and the structural inequities that shape nutritional outcomes worldwide.

This article offers a clinically grounded and epidemiologically informed account of vitamin D deficiency symptoms, their biological basis, the populations at greatest risk, and the particular implications for Sub-Saharan Africa. The evidence base is substantial; the policy response has been, on the whole, inadequate.

What Vitamin D Does - and Why Deficiency Matters

Vitamin D is a fat-soluble secosteroid that functions less like a conventional vitamin and more like a hormone. After cutaneous synthesis or dietary absorption, it undergoes two sequential hydroxylation steps - first in the liver to form 25-hydroxyvitamin D [25(OH)D], and then in the kidneys to form the biologically active 1,25-dihydroxyvitamin D (calcitriol). Calcitriol binds the nuclear vitamin D receptor (VDR), which is expressed in virtually every tissue in the body, regulating the transcription of hundreds of genes ( Holick, 2007 ).

The classical actions of vitamin D centre on calcium and phosphate homeostasis. Calcitriol promotes intestinal absorption of calcium, reduces renal calcium excretion, and - in concert with parathyroid hormone (PTH) - mobilises calcium from bone. Deficiency disrupts this system predictably: calcium absorption falls, PTH rises, bone mineralisation falters, and skeletal pathology ensues. But vitamin D’s reach extends well beyond the skeleton. VDR expression in immune cells, pancreatic beta cells, cardiomyocytes, and neurons implies roles in immune modulation, insulin secretion, cardiovascular function, and neurodevelopment. These non-classical roles remain an active area of investigation, though the mechanistic plausibility is increasingly well supported ( Bikle, 2014 ).

Deficiency is defined by serum 25(OH)D concentration. The most widely used thresholds classify deficiency as <50 nmol/L (20 ng/mL), with severe deficiency at <25 nmol/L; insufficiency typically spans 50–75 nmol/L. Some authorities advocate higher optimal thresholds, though the debate remains unresolved. The biological consequences across this spectrum are graduated rather than binary.

Recognising Vitamin D Deficiency Symptoms

Musculoskeletal Manifestations

The most clinically recognisable vitamin d deficiency symptoms are skeletal. In children, severe, prolonged deficiency causes nutritional rickets - a condition characterised by impaired endochondral ossification leading to bowing of the long bones, widening of the wrists and ankles (rachitic rosary at the costochondral junctions), craniotabes, delayed dentition, and frontal bossing. Motor developmental delay and hypotonia frequently accompany these structural changes. The global burden of nutritional rickets was long underestimated; a systematic review and meta-analysis identified it as a problem of striking magnitude in Sub-Saharan Africa and parts of Asia, particularly in populations where dietary calcium intake is low irrespective of vitamin D status ( Munns et al., 2016 ).

In adults, vitamin D deficiency causes osteomalacia - a failure of normal bone matrix mineralisation. Patients present with diffuse, poorly localised musculoskeletal pain, often described as a deep, dull ache in the back, pelvis, hips, and thighs. Muscle weakness, particularly proximal, is characteristic; patients may have difficulty rising from a chair or climbing stairs. Fractures in the setting of low bone mineral density are a consequence of longer-term deficiency. Osteoporosis risk is amplified in postmenopausal women and older adults who are already subject to age-related bone loss.

Fatigue, Mood, and Neurocognitive Symptoms

Persistent fatigue and low mood are frequently reported by patients with documented deficiency, though the causal relationship is difficult to isolate. Vitamin D receptors in the hippocampus and prefrontal cortex, alongside its role in serotonin biosynthesis and neuroprotection, provide a plausible mechanistic basis. Observational studies have reported associations between low 25(OH)D and depressive symptoms, cognitive decline, and reduced quality of life, though intervention trials have produced mixed results - likely reflecting heterogeneity in baseline status, dose, and outcome definition ( Palacios & Gonzalez, 2014 ).

Immune Dysregulation

Vitamin D is required for the transcription of antimicrobial peptides - including cathelicidins and defensins - in macrophages responding to intracellular pathogens. Deficiency has been associated with increased susceptibility to respiratory infections, tuberculosis, and, more recently, with adverse COVID-19 outcomes. The modulatory effects on T-cell differentiation also implicate low vitamin D in autoimmune conditions, including multiple sclerosis, type 1 diabetes, and inflammatory bowel disease. These associations are robust at the epidemiological level; causality remains under investigation ( Pilz et al., 2019 ).

Cardiovascular and Metabolic Signals

Cross-sectional data link vitamin D deficiency with hypertension, insulin resistance, and dyslipidaemia. The proposed mechanisms include vitamin D’s suppression of the renin-angiotensin system, its promotion of insulin secretion, and its anti-inflammatory actions. Whether correcting deficiency translates into cardiovascular event reduction remains debated, with large supplementation trials yielding null or modest results in populations without severe deficiency.

Who Is Deficient and Why: Epidemiology and Risk Factors

Global Prevalence

Population-level data on vitamin D deficiency are striking. In the United States, approximately 41.6% of adults have serum 25(OH)D below 50 nmol/L, with substantially higher prevalence among non-Hispanic Black (82.1%) and Hispanic (69.2%) individuals ( Forrest & Stuhldreher, 2011 ). European surveys reveal similar patterns, particularly in northern latitudes during winter months. Among hospitalised patients and older adults in care facilities, rates exceed 80% in some studies.

Skin Pigmentation and Latitude

Melanin is an efficient absorber of UVB radiation - the waveband responsible for cutaneous vitamin D synthesis. Deeply pigmented skin requires substantially longer sun exposure to achieve equivalent 25(OH)D synthesis to lightly pigmented skin. This biological reality interacts with latitude: at latitudes above approximately 35 degrees north or south, UVB irradiance during winter months is insufficient for meaningful cutaneous synthesis regardless of pigmentation. The combination of dark skin and high latitude - common among African and South Asian immigrant communities in Europe and North America - creates particularly pronounced vulnerability ( Lips, 2010 ).

The South Asian Paradox and the Indian Experience

India presents a striking example of what has been termed a “sunshine paradox”: despite abundant UVB irradiance throughout the year across most of the country, vitamin D deficiency is estimated to affect 70–100% of certain population groups, including urban professionals, schoolchildren, and pregnant women. The reasons are multifactorial: air pollution and particulate matter attenuate UVB irradiance in major cities; cultural clothing norms limit skin exposure; indoor sedentary work has replaced outdoor activity; and dietary sources of vitamin D in traditional South Asian diets are limited ( Ritu & Gupta, 2014 ). The Indian experience is instructive for Sub-Saharan Africa, where comparable transitions - rapid urbanisation, changed working patterns, rising pollution - are now underway.

Sub-Saharan Africa: A Counterintuitive Burden

Vitamin D deficiency in Sub-Saharan Africa (SSA) demands specific attention. The conventional assumption - that equatorial populations are protected by year-round sun exposure - is empirically unsupported. Studies from Nigeria, Ethiopia, South Africa, Tanzania, and across West Africa document clinically significant deficiency in children and adults alike.

The drivers are varied. In urban West Africa, children spend increasing proportions of their time indoors; school attendance, often enforced in enclosed buildings, limits midday sun exposure during peak UVB hours. Cultural norms around clothing and shade-seeking behaviour, particularly for girls and women in certain communities, reduce effective exposure. Exclusive breastfeeding - nutritionally optimal in virtually every other respect - provides limited vitamin D when the mother herself is deficient. Air pollution in rapidly expanding cities such as Lagos, Nairobi, Accra, and Addis Ababa is an underappreciated factor attenuating UVB at the surface level.

Dietary patterns in SSA offer limited vitamin D compensation. Fatty fish, egg yolks, and fortified dairy products - the principal dietary sources - are inaccessible to a large proportion of lower-income households. Fortification programmes, which have substantially reduced deficiency in some high-income countries, remain limited in coverage and implementation quality across most of SSA. As discussed in the article on the role of micronutrient interventions , targeted supplementation and fortification offer the most promising near-term policy instruments.

The nutritional rickets burden in SSA deserves special mention. Uniquely, rickets in parts of West and East Africa presents even in the context of adequate vitamin D status - driven instead by dietary calcium deficiency. This calcium-deficiency rickets phenotype, now well characterised, requires different therapeutic and preventive approaches and should not be conflated with the classical vitamin D-deficiency rickets prevalent in temperate populations.

Adolescents: A Particularly Vulnerable Group

Adolescence is a period of rapid skeletal growth, with approximately 40% of peak bone mass accrued during this window. Inadequate vitamin D during adolescence compromises mineralisation at a critical juncture, increasing long-term fracture risk and osteoporosis risk in older adulthood. Adolescent girls in SSA bear compounded risk: menstrual blood losses (increasing iron demands that may indirectly affect nutritional status), cultural norms limiting sun exposure, and the approach of the reproductive years - when deficiency has consequences for foetal skeletal development and maternal bone health - all intersect. Monitoring systems that track adolescent vitamin D status remain sparse; this gap is examined in the context of the evolution of public health monitoring .

Causes and Contributing Factors: A Systems View

The causes of vitamin D deficiency operate at multiple levels:

Biological: Malabsorption syndromes (coeliac disease, Crohn’s disease, cystic fibrosis) impair fat-soluble vitamin absorption. Obesity sequesters vitamin D in adipose tissue, reducing its bioavailability. Chronic kidney disease impairs the renal hydroxylation step. Certain medications - anticonvulsants, glucocorticoids, rifampicin - accelerate vitamin D catabolism.

Behavioural and cultural: Sun-avoidance behaviours, indoor occupational patterns, and clothing norms reduce cutaneous synthesis regardless of ambient UVB availability.

Dietary: Low consumption of vitamin D-rich foods, and the absence or inadequacy of food fortification programmes, limits dietary compensation.

Environmental: Latitude, seasonality, cloud cover, altitude, and air pollution all modulate UVB availability at the earth’s surface.

Structural: Poverty constrains dietary diversity and access to fortified foods; healthcare systems in low-income settings rarely have capacity for routine vitamin D monitoring.

Diagnosis and Treatment

Serum 25(OH)D measurement by chemiluminescence immunoassay or LC-MS/MS remains the gold standard for assessment. Routine screening of the general population is not supported by evidence in high-income settings; targeted testing of at-risk groups - including pregnant women, infants, adolescents, the elderly, individuals with dark skin at high latitude, and those with conditions affecting absorption or metabolism - is warranted.

Treatment depends on the degree of deficiency and the clinical context. For nutritional rickets in children, high-dose vitamin D2 or D3 (typically 1,000–5,000 IU/day, or a single high-dose “stosstherapy”) combined with adequate calcium intake produces reliable biochemical and clinical response. In adults with osteomalacia, similar regimens over 8–12 weeks achieve normalisation of 25(OH)D and resolution of bone pain in most patients. Maintenance supplementation at 400–2,000 IU/day is appropriate for ongoing at-risk individuals. Vitamin D3 (cholecalciferol) appears marginally more effective than D2 (ergocalciferol) at raising and sustaining serum concentrations.

Limitations of the Evidence Base

Any honest appraisal of the vitamin D literature must acknowledge its methodological limitations.

Observational confounding: Most evidence linking vitamin D deficiency to non-skeletal outcomes - depression, cardiovascular disease, cancer, infectious susceptibility - derives from observational studies. Vitamin D status correlates with outdoor activity, socioeconomic position, diet quality, and obesity, all of which are independently associated with the outcomes of interest. Residual confounding is a persistent concern.

Heterogeneity in RCTs: Supplementation trials vary substantially in baseline 25(OH)D levels of enrolled participants, dose regimens, duration of follow-up, and outcome definitions. Pooling these trials produces estimates of uncertain validity. Trials conducted in already-replete populations are unlikely to show benefit; trials in genuinely deficient populations remain underrepresented.

Measurement variability: 25(OH)D assays from different manufacturers show meaningful inter-laboratory variation, complicating cross-study comparisons and population-level threshold-setting.

SSA data gaps: Population-representative data on vitamin D status across Sub-Saharan Africa are sparse. Most published studies are from urban clinical populations, small samples, or non-representative convenience samples. The true burden across the region remains poorly characterised, and the relative contributions of vitamin D deficiency versus dietary calcium deficiency to the rickets burden are not fully disentangled.

Intervention evidence from LMICs: The majority of supplementation and fortification trials have been conducted in high-income settings. Extrapolation to low- and middle-income country contexts - where baseline dietary patterns, sun exposure behaviours, and concurrent micronutrient deficiencies differ substantially - is problematic.

Frequently Asked Questions

Can people in sunny climates be vitamin D deficient?

Yes - and the evidence from Sub-Saharan Africa, South Asia, and the Middle East makes this unambiguous. Equatorial location does not confer protection if sun exposure is limited by indoor work, cultural dress, air pollution, or behavioural sun-avoidance. Melanin concentration in the skin is also a modifying factor. The “sunny country paradox” is now well documented across multiple regions and should not be used to dismiss vitamin D deficiency concerns in tropical populations.

What is the difference between vitamin D deficiency and insufficiency?

Deficiency typically refers to serum 25(OH)D below 50 nmol/L (20 ng/mL), a threshold associated with impaired calcium absorption, elevated PTH, and increased fracture risk. Insufficiency spans 50–75 nmol/L and may carry subtler health implications. Severe deficiency, below 25 nmol/L, produces frank skeletal disease - rickets in children, osteomalacia in adults. These thresholds remain somewhat contested and may need adjustment for specific populations or outcomes.

Does vitamin D supplementation prevent respiratory infections?

The evidence is suggestive but not conclusive. A 2017 individual participant data meta-analysis reported a modest protective effect of daily or weekly supplementation against acute respiratory tract infections, particularly in those with baseline 25(OH)D below 25 nmol/L. Bolus dosing appeared less effective. Mechanistically, vitamin D induction of antimicrobial peptides in epithelial cells and macrophages provides a plausible basis. However, effect sizes are small and trial quality is variable; supplementation should not be positioned as a primary infection prevention strategy.

Are vitamin D supplements safe at higher doses?

Vitamin D toxicity - hypercalcaemia, hypercalciuria, and soft tissue calcification - requires sustained intake well above therapeutic supplementation doses, typically exceeding 10,000 IU/day for months. The range between adequate and toxic intake is therefore quite wide. However, bolus dosing regimens (e.g., single doses of 300,000–600,000 IU) have in some trials been associated with paradoxical increases in falls and fractures in older adults, suggesting that pharmacokinetic factors matter beyond simple cumulative dose. Routine supplementation at 400–2,000 IU/day carries no meaningful safety concerns for the general adult population.

Conclusion

Vitamin D deficiency is a global health problem that cuts across latitude, income level, and sun exposure. Its vitamin d deficiency symptoms range from the unmistakable - bowed legs in a child, bone pain and proximal weakness in an adult - to the diffuse and easy to attribute elsewhere: fatigue, low mood, recurrent infections. The global burden is highest not where it is most expected but where a confluence of urbanisation, cultural practices, dietary poverty, and pigmentation biology create conditions for deficiency even under equatorial skies.

SSA faces a particular and underappreciated challenge. Nutritional rickets remains a meaningful cause of childhood disability. Adolescent girls are inadequately monitored. Fortification and supplementation programmes are patchy. Surveillance systems lack the reach and regularity to characterise population-level status. Addressing these gaps requires investment in both monitoring capacity and targeted public health intervention - and a willingness to treat vitamin D not as a high-income-country concern but as one of the neglected nutritional priorities of a rapidly urbanising developing world.

Dr. Amara Osei is an epidemiologist and public health nutritionist specialising in micronutrient deficiencies and maternal and child health in Sub-Saharan Africa.